dr. nancy l. lewis on resistance among gist patients and regorafenib
Published 11 years ago • 87 plays • Length 1:18Download video MP4
Download video MP3
Similar videos
-
1:30
dr. nancy l. lewis discusses the correct trial for regorafenib in metastatic colorectal cancer
-
1:20
dr. nancy l. lewis on targeted therapies in gastroesophageal cancer
-
2:48
dr. nancy l. lewis explains the implications of the grid study
-
1:23
dr. george demetri discusses regorafenib for patients with gist trial results
-
2:38
third-line therapy for gist
-
1:49
dr. george demetri describes the mechanism of action of regorafenib in gist
-
9:34
regorafenib in colorectal cancer
-
2:30
second- and third-line therapies in colorectal cancer
-
1:02
regorafenib as a treatment for gist (gastrointestinal stromal tumour) patients
-
6:17
multidisciplinary consensus for the definition of resectable nsclc
-
1:36
optimal dosing of regorafenib in colorectal cancer
-
5:32
colorectal cancer: regorafenib patient selection and dosing
-
0:41
netrf session 4 finding the causes of multifocal intestinal nets
-
5:23
what you need to know about colorectal cancer
-
1:41
gastrointestinal stromal tumour
-
2:58
challenges in staging urinary tract tumors
-
37:10
live from the nih gist clinic
-
3:18
what is colorectal cancer?
-
2:18
what to know about colorectal cancer risk & screenings